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Superior vena cava syndrome
a b s t r a c t
INTRODUCTION: Superior vena cava syndrome (SVCS) is obstruction of blood ﬂow through the SVC. It is
a medical emergency and most often manifests in patients with a malignant disease process within the
thorax. A patient with SVCS requires immediate diagnostic evaluation and therapy.
PRESENTATION OF CASE: A 33-years-old woman presented with complaints of dyspnoea and chest pain.
Computer tomography revealed a large mass in the anterior mediastinum. This mass compressed sur-
rounding structures. Stenting was indicated for early symptoms of SVCS. The diagnosis of Hodgkin’s
lymphoma (HL) was conﬁrmed with biopsy. The patient’s stage II HL has been subsequently treated with
six cycles of chemotherapy with doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD), followed by
radiotherapy. Presently she is doing well.
DISCUSSION:Although lymphomas are a common cause of SVCS but almost always SVCS is caused by non-
Hodgkin’s lymphoma (NHL). HL despite its common presentation with mediastinal lymphadenopathy
rarely causes SVCS.
CONCLUSION:Lymphomasarea commoncauseof SVCS inyoungage.HLmaypresent asSVCS. Pathological
conﬁrmation of diagnosis should be done before initiating therapywhile dealingwith a case of SVCS. SVC
stenting is effective and has few complications in patients with SVCS.
© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Themediastinum is the cavity that separates the lungs from the
rest of the chest [1]. More than two thirds of mediastinal tumors
are benign, masses in the anterior compartment are more likely
to be malignant [2]. Localizing symptoms are secondary to tumor
invasion. Common localizing symptoms include respiratory com-
promise, dysphagia, paralysis of the limbs, diaphragm, and vocal
cords, Horner syndrome, and superior vena cava syndrome (SVCS).
Systemic symptoms are typically due to the release of excess hor-
mones, antibodies or cytokines [3].
SVCS includes various clinical signs and symptoms due to exter-
nal compression of the SVC itself or greater veins emptying into
the SVC or the superior cavo-atrial junction, resulting in reduced
blood ﬂow. The assessment of a patient with SVCSmust be prompt.
The optimal treatment choice should be decided with an inter-
disciplinary consensus [4]. Although lymphomas are a common
cause of SVCS but almost always SVCS is caused by non-Hodgkin’s
lymphoma (NHL). Hodgkin’s lymphoma (HL) despite its common
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presentation with mediastinal lymphadenopathy rarely causes
SVCS [5].
2. Presentation of case
A 33-years-old woman was hospitalized at the Department of
Pulmonology and Phthisiology, Martin University Hospital with
mediastinal mass ﬁnding on conventional chest radiography in
October 2011. The patient was hospitalized on the recommen-
dation of local pulmonologist, who ordered a chest X-ray for
differential diagnosis of dyspnoea and chest pain. It revealedhomo-
geneous dark area on the right chest side.
The patient reported a two-week history of progressive dysp-
noea after exertion, dry irritating cough, and mild chest pain. She
complained from night sweats but without fever. She also referred
with a weight loss of 10kg for the last 3 weeks. She had no experi-
ence with chest oppressions or heart palpitations but she suffered
from occasional dizziness.
On physical examination, temperature was normal, blood pres-
sure was 130/80mmHg in both arms, pulse rate is 96/min, and
respiration rate is 26/min. Pulses were symmetric and equal in all
extremities. There was marked facial oedema. The skin was pale,
anicteric, with no signs of bleeding or peripheral cyanosis. Her neck
veins were distended, prominent veins were present on whole of
the chest wall and the ﬂow in these veins was from above down-
http://dx.doi.org/10.1016/j.ijscr.2015.06.017
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creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. Postcontrast CT images at the level of crossing of left brachiocephalic vein
and arch of aorta showing a large homogeneously enhancingmass lesion in anterior
mediastinum (October, 2011).
wards. On examination of respiratory system there was dullness
on percussion over right side of chest at infraclavicular, supras-
capular and interscapular areas, vocal resonance andvocal fremitus
was also reduced in these areas and therewere decreased intensity
of breath sounds in these areas. Heartbeat was regular, without
murmurs. The liver did not exceed the costal margin, the spleen
was not felt and there was no mass in the abdomen. Peripheral
lymphadenopathy was not present.
According to medical records, in June 2000, she underwent
appendectomy. There was no other personal or family history. She
had allergic contact dermatitis from nickel.
Based on classical clinical features of swelling over upper body,
dilated veins over neck and chest, dyspnoea and dysphagia a pro-
visional diagnosis of SVCS was made and she was investigated
further.
2.1. Investigations
Laboratory tests on the day of admission revealedmild anaemia
(haemoglobin level 11g/dL). Total leucocyte count was 8500/mm3
and differential leucocyte count was neutrophils 71% and lympho-
cytes 29%. The biochemical tests like liver and renal function tests
were within normal limits. Bronchoscopy demonstrated stenosis
of the right lower lobe bronchus. Segmental bronchi were also
closed. Computed tomography (CT) scan revealed a mass in ante-
rior mediastinum. This mass compressed the surrounding vascular
structures (Fig. 1). Therefore, a thoracic surgeon was consulted.
Anteriormediastinotomywas indicated. In early October, the oper-
ationwasperformed for tissuebiopsyandpleural effusion. For early
symptoms of the SVCS a stentwas inserted into the SVC (Fig. 2). The
procedure was performedwith the patient under local anaesthesia
(1% mesocain) in the angiographic suite (equipped with a ﬂuoro-
scopic machine; Siemens, Munich, Germany) and was performed
by an interventional team assisted by an anaesthesiologist for car-
diocirculatory and airway support. Intubation was not necessary.
Venography was performed to evaluate the location, length, and
severity of the stenosis. The right common femoral vein was used
as the approach site to access the SVC. After puncture of femoral
vein, a 6-F sheath was inserted. The stenosis of the SVC was nego-
tiated with a 5-F catheter and a 0.035-in hydrophilic guidewire
that was 150 cm in length. The pressure gradient between the
brachiocephalic vein or the internal jugular vein and the right
atrium was measured before inserting the stent. Predilation was
performed with a 6mm (diameter) balloon catheter to determine
stent size and to facilitate easy navigation of the stenosis and
placement of the stent. We used the self-expanding nitinol Sinus-
XL stent (OptiMed, Ettlingen, Germany). Heparin (4000units) was
administered intravenously prior to these procedures. Warfarin
administration was continued for 18 months followed by aspirin
administration (81mg/day). The postoperative period passedwith-
out any complications. Histologic analysis revealed a Hodgkin’s
lymphoma (HL). Therefore, the patient was moved to the Depart-
mentofHaematologyandTransfusiology inorder to start treatment
and complet the staging. In thebeginningof theﬁrst hospitalization
the trephine biopsy excluded inﬁltration of bone marrow.
2.2. Treatment
The ﬁrst cycle of ABVD immunochemotherapy was admin-
istered in early November. ABVD is an acronym for different
chemotherapeutic drugs. “A” stands for adriamycin; “B” for
bleomycin; “O” for vinblastine; and “D” for dacarbazine. All
drugs were given intravenously on days 1 and 15 (doxorubicin
25mg/m2, bleomycin 10mg/m2, vinblastine 6mg/m2 and dacar-
bacine 375mg/m2). The treatment was repeated every 4 weeks.
2.3. Outcome and follow-up
After four cycles of chemotherapy CT showed regression of
tumor, so itwas decided to continuewith the treatment (Fig. 3). The
last (sixth) cycle of chemotherapywas administered inMarch2012.
RestagingCTexamination revealedpersistent tumor6×5×3 cm in
size. Based on this ﬁnding, external radiotherapy (ERT) inmediasti-
nal region was indicated. The ERT consisted of a dose of 36Gy in 6
fractions over.
Fig. 2. Angiography shows SVC stenting in our patient.
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Fig. 3. Postcontrast CT images at the level of crossing of left brachiocephalic vein
and arch of aorta showing regression of tumor mass (January, 2011).
Three months later, we performed positron emission tomog-
raphy, which showed complete metabolic remission of the disease
Fig. 4. At present the patient is in haematology outpatient carewith
no signs of relapse. In December 2013, she gave birth to healthy
twins.
3. Discussion
SVCS is obstruction of blood ﬂow through the SVC. It is amedical
emergency and most often manifests in patients with a malignant
disease process within the thorax. A patient with SVCS requires
immediate diagnostic evaluation and therapy. Intrathoracic malig-
nancies are responsible for 60–85% of SVCS cases. SVC obstruction
is the presenting symptom of a previously undiagnosed tumor in
up to 60% of these cases [6,7]. Non-small-cell lung cancer (NSCLC) is
the most common malignant cause of SVCS, accounting for 50% of
all cases, followed by small-cell lung cancer (SCLC) (25%) and NHL
(10%) [6]. Lung cancer and NHL account for approximately 95% of
all malignant SVCS cases [6]. In young age, malignant lymphoma
is the leading cause of SVCS. HL involves the mediastinum more
commonly than any other lymphoma but rarely causes SVCS [5].
Fig. 4. Positron emission tomography showed completemetabolic remission of the
disease (August, 2012).
The diagnosis of a large mediastinal mass can be made on a
conventional chest radiograph. For a more detailed visualization
of the SVC and its surrounding structures, a chest CT with intra-
venous contrast medium in the venous phase is recommended.
Alternatively, magnetic resonance imaging (MRI) with MRI phle-
bocavography can be performed [8].
Theunderlyingdisease determines the treatment of SVCS, so the
cornerstone of the treatment of thoracic malignancies is accurate
diagnosis. It is desirable and most of the times possible to make
a histological diagnosis of malignancy before going for treatment.
Treatment without an established tissue diagnosis should be initi-
ated only when the symptoms are rapidly progressive or multiple
previous attempts to make a tissue diagnosis have failed [9]. In
addition, cytological methods such as protected specimen brush,
bronchial washing, or bronchoalveolar lavage tend to increase the
diagnostic yield [9].
The primary goal in SVCS management is alleviation of symp-
tomsand treatmentof theunderlyingdisease. Supportivemeasures
like head end elevation, oxygen inhalation and diuretics are helpful
in patients of SVCS due to any cause, dexamethasone also provides
symptomatic relief by decreasing oedema and tumour burden in
malignant causes of SVCS. In presence of acute thrombus throm-
bolysis is indicated [10]. Catheter induced SVCS can be managed
with the help of anticoagulants, thrombolysis and endovascular
treatment [11]. The placement of stent in vena cava superior can
restore venous return with following prompt symptom relief [12].
There are still a few unanswered questions regarding interven-
tional technique and medication before and after stent placement.
Some authors recommend pre-dilatation of the vein before stent
placement, and others perform primary stenting followed by post-
dilatation [13,14]. The anticoagulation therapy is also controversial,
and there is no consensus about it due to bleeding risk. Some recent
results suggest that there are no differences between patients who
received anticoagulation therapy and/or aspirin and patients who
do not receive scheduled anticoagulation therapy in terms of stent
thrombosis [15]. Themajority of patients record complete or signif-
icant disappearance of head andupper extremity oedema, followed
by reduction of headache, dyspnoea, and collateral venous circula-
tion [15,16]. The systemic review from Rowell and Gleeson [17] is
the biggest collected data which show symptom relief in 95% of
the patients treated with stent placement and relapse in up to 11%.
Complications after stent insertion are relatively rare and include
stent fracture and migration (10%), pulmonary emboli, and local
groin hematoma, but several fatal cases are reported after inter-
vention with pericardial tamponade [18].
HL is a B cell-derived lymphoidmalignancywith an incidence of
2–3/100000/year. Young adults aged 20–40 aremost often affected
[19]. Most patients of HL present with palpable lymphadenopa-
thy that is non-tender, in most patients these lymph nodes are in
the neck, supraclavicular area and axilla [20]. More than half the
patients will have mediastinal adenopathy at diagnosis and this
is sometimes the initial manifestation [20]. Despite this common
occurrenceofmediastinal involvement inHLSVCS rarely occurs [5].
One-third of the patients present with fever, night sweats and/or
weight loss. Due to the development of highly active multiagent
chemotherapy regimens such as ABVD as well as the optimization
of radiotherapy ﬁeld and doses, HL has become highly curable and
about 80% of patients remain relapse-free after adequate ﬁrst-line
treatment.
4. Conclusion
SVCS is a medical emergency; most often manifests in patients
with a malignant disease process within the thorax. HL involves
the mediastinum more commonly than any other lymphoma but
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rarely causes SVCS. Therefore, pathological conﬁrmation of diag-
nosis should be done before initiating therapy while dealing with
a case of SVCS. SVC stenting is effective treatment and has few
complications in patients with SVCS.
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